Eli Lilly (LLY)

How LLY actually reacts to news — the realized, point-in-time move the market made, measured across 2,000+ labeled events over the last three years with zero look-ahead.

Track LLY free See the full LLY reaction history →

The quantified answer

LLY’s median reaction, across the day.

+0.03%

Median 30-min

Typical reaction 30 minutes after any LLY news

52%

Moved up

Share of LLY news events that rose at 30 minutes

-0.07%

Median to close

Where LLY typically settles by the closing bell

Median move vs. the price at the news timestamp, across 2,000+ labeled events.

By event type

How LLY reacts, by analyst action.

Event	Events	Median 30-min	% positive	Median to close
Analyst upgrades	45	-0.13%	47%	-0.29%
Analyst downgrades	32	+0.12%	56%	-0.06%
Coverage initiations	28	+0.06%	50%	-0.83%
Rating reiterations	243	+0.01%	53%	-0.03%
Price-target raises	100	+0.07%	57%	+0.18%
Price-target cuts	16	+0.17%	56%	-0.23%

Last 3 years, pulled 2026-07-14. Reaction = percent move vs. the price at the news timestamp. The same measurement runs across every name in the dataset.

That’s how LLY usually reacts — get an email when it moves on news →

Next time, know first

Email me when LLY moves on news.

One email per qualifying move — the headline, the measured reaction, and how it compares to LLY’s baseline. Nothing else.

Prefer a one-pager?

Get “How LLY reacts to news” as a PDF.

A free one-page summary: LLY’s median reaction to news and the full breakdown by event type — the numbers on this page, in one page.

Recent LLY events, each with its measured reaction. (Page 1 of 8.)

Date	Headline	Event	Source	5-min	To close
Aug 12, 2026	Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market	Press release	PR Newswire	+0.17%	+1.67%
Aug 5, 2026	Form 10-Q ELI LILLY & Co For: Jun 30	SEC filing · Form 10-Q	SEC EDGAR	+0.15%	+0.96%
Aug 5, 2026	Form 8-K ELI LILLY & Co For: Aug 05	SEC filing · Form 8-K	SEC EDGAR	+2.15%	-1.59%
Aug 5, 2026	Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress	Press release	PR Newswire	+2.15%	-1.59%
Aug 3, 2026	Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer	Press release	PR Newswire	-1.07%	-2.66%
Jul 23, 2026	Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C	Press release	PR Newswire	+2.07%	+3.84%
Jul 22, 2026	Lilly confirms date and conference call for second-quarter 2026 financial results announcement	Press release	PR Newswire	+0.01%	+0.26%
Jul 16, 2026	Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions	Press release	PR Newswire	-0.78%	+1.23%
Jul 9, 2026	Lilly to present Alzheimer's disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatment	Press release	PR Newswire	+1.26%	+0.44%
Jul 8, 2026	Lilly Canada receives long-awaited Ebglyss® CDA-AMC recommendation as well as pCPA LOI for atopic dermatitis (eczema)	Press release	Canada Newswire	+0.56%	+0.33%
Jun 26, 2026	Lilly launches "The Memory Radio Station" across Europe, inviting the public to visually reconstruct fading memories through GenAI	Press release	PR Newswire	+2.00%	+7.03%
Jun 26, 2026	Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy	Press release	PR Newswire	+2.00%	+7.03%
Jun 25, 2026	What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management	Press release	PR Newswire	-1.35%	-0.45%
Jun 24, 2026	Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders	Press release	PR Newswire	-0.56%	-1.56%
Jun 23, 2026	Form 11-K ELI LILLY & Co For: Dec 31	SEC filing · Form 11-K	SEC EDGAR	+0.17%	-0.02%
Jun 22, 2026	Lilly declares third-quarter 2026 dividend	Press release	PR Newswire	-0.25%	+0.20%
Jun 14, 2026	Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL	Press release	PR Newswire	-1.68%	-0.41%
Jun 13, 2026	Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting	Press release	PR Newswire	-1.68%	-0.41%
Jun 10, 2026	Zepbound (tirzepatide) and Shaquille O'Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatable	Press release	PR Newswire	-0.29%	-1.25%
Jun 9, 2026	Convatec and Lilly Foundation Commit $5m to Partners In Health to Improve Care for Non-communicable Disease and Chronic Conditions	Press release	Business Wire	+0.12%	-1.57%
Jun 9, 2026	FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis	Press release	PR Newswire	-0.29%	-1.25%
Jun 8, 2026	Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials	Press release	PR Newswire	-0.16%	-0.81%
Jun 7, 2026	Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause	Press release	PR Newswire	-0.03%	-0.81%
Jun 6, 2026	Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications	Press release	PR Newswire	-0.03%	-0.81%
Jun 2, 2026	Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual Meeting	Press release	PR Newswire	+0.98%	-0.15%
May 31, 2026	Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer	Press release	PR Newswire	-0.93%	-1.64%
May 28, 2026	Foundayo and Zepbound now covered for millions of Americans	Press release	PR Newswire	+0.93%	+2.62%
May 28, 2026	Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care	Press release	PR Newswire	-0.15%	+0.04%
May 27, 2026	Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference	Press release	PR Newswire	-0.14%	-0.46%
May 26, 2026	Lilly announces three acquisitions to build infectious disease portfolio	Press release	PR Newswire	-0.20%	-1.00%
May 25, 2026	A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia	Press release	PR Newswire	-0.20%	-1.00%
May 21, 2026	Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting	Press release	PR Newswire	+0.80%	+1.43%
May 21, 2026	Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial	Press release	PR Newswire	-0.02%	+1.43%
May 20, 2026	Form 8-K ELI LILLY & Co For: May 20	SEC filing · Form 8-K	SEC EDGAR	-0.02%	+1.43%
May 18, 2026	Lilly to participate in Bernstein's 42nd Annual Strategic Decisions Conference	Press release	PR Newswire	-0.31%	-0.58%
May 16, 2026	Lilly, Caitlin Clark Foundation, and Musco Lighting open three community sports courts in Indianapolis, expanding year-round access for youth	Press release	PR Newswire	-1.27%	-1.25%
May 14, 2026	Lilly and UNICEF collaborate to give millions of children a healthier start	Press release	PR Newswire	-1.13%	-1.06%
May 12, 2026	In honor of its 150th anniversary, Eli Lilly and Company commits to support community organizations aiming to provide 500,000 meals and cold storage for 150 food pantries	Press release	PR Newswire	-0.26%	-0.32%
May 12, 2026	Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials	Press release	PR Newswire	-0.16%	+1.97%
May 11, 2026	Form SD ELI LILLY & Co	SEC filing · Form SD	SEC EDGAR	+0.02%	+1.52%
May 11, 2026	The Next Generation of the GLP-1 Revolution Is Already Underway	Press release	GlobeNewswire	+2.16%	+2.34%
May 7, 2026	Form 8-K ELI LILLY & Co For: May 04	SEC filing · Form 8-K	SEC EDGAR	-0.07%	-2.63%
May 6, 2026	Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility	Press release	PR Newswire	-0.53%	-0.43%
May 5, 2026	Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years	Press release	PR Newswire	-0.28%	+1.74%
May 4, 2026	HEALTH CANADA AUTHORIZES LILLY'S KISUNLA™ (DONANEMAB), A NEW TREATMENT FOR EARLY ALZHEIMER'S DISEASE	Press release	Canada Newswire	+0.90%	+0.94%
May 4, 2026	Lilly declares second-quarter 2026 dividend	Press release	PR Newswire	-0.00%	+0.76%
May 1, 2026	PDA Releases Revised Technical Reports on Process Validation and Biologics Reprocessing to Support Manufacturing Excellence	Press release	PR Web	+0.90%	+0.94%
Apr 30, 2026	Form 10-Q ELI LILLY & Co For: Mar 31	SEC filing · Form 10-Q	SEC EDGAR	+0.01%	+1.36%
Apr 30, 2026	Form 8-K ELI LILLY & Co For: Apr 30	SEC filing · Form 8-K	SEC EDGAR	+0.60%	+3.84%
Apr 30, 2026	Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines	Press release	PR Newswire	+0.60%	+3.84%

Each headline opens its own page with the full realized reaction — the move the market actually made, measured from the news timestamp.

Keep exploring

More of the dataset.

LLY earnings → · Analyst actions → · SEC filings → · Full history →

Every ticker we measure the same way24

Eli Lilly (LLY)

LLY’s median reaction, across the day.

How LLY reacts, by analyst action.

Email me when LLY moves on news.

Get “How LLY reacts to news” as a PDF.

Recent LLY events, each with its measured reaction. (Page 1 of 8.)

More of the dataset.

Apple (AAPL)

NVIDIA (NVDA)

Tesla (TSLA)

Microsoft (MSFT)

Advanced Micro Devices (AMD)

Amazon (AMZN)

Alphabet (GOOG)

Meta Platforms (META)

Broadcom (AVGO)

JPMorgan Chase (JPM)

Visa (V)

Walmart (WMT)

UnitedHealth Group (UNH)

Netflix (NFLX)

Johnson & Johnson (JNJ)

Exxon Mobil (XOM)

Home Depot (HD)

Costco (COST)

Mastercard (MA)

Oracle (ORCL)

Salesforce (CRM)

Bank of America (BAC)

Coca-Cola (KO)

Walt Disney (DIS)

Browse all tickers

You just saw one reaction.
There are 26 million more.

Know the next move, measured.

The dataset, one command away.

Eli Lilly (LLY)

LLY’s median reaction, across the day.

How LLY reacts, by analyst action.

Email me when LLY moves on news.

Get “How LLY reacts to news” as a PDF.

Recent LLY events, each with its measured reaction. (Page 1 of 8.)

More of the dataset.

Apple (AAPL)

NVIDIA (NVDA)

Tesla (TSLA)

Microsoft (MSFT)

Advanced Micro Devices (AMD)

Amazon (AMZN)

Alphabet (GOOG)

Meta Platforms (META)

Broadcom (AVGO)

JPMorgan Chase (JPM)

Visa (V)

Walmart (WMT)

UnitedHealth Group (UNH)

Netflix (NFLX)

Johnson & Johnson (JNJ)

Exxon Mobil (XOM)

Home Depot (HD)

Costco (COST)

Mastercard (MA)

Oracle (ORCL)

Salesforce (CRM)

Bank of America (BAC)

Coca-Cola (KO)

Walt Disney (DIS)

Browse all tickers

You just saw one reaction.There are 26 million more.

Know the next move, measured.

The dataset, one command away.

You just saw one reaction.
There are 26 million more.